Summary

Eligibility
for people ages 18 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at Orange, California
Dates
study started
estimated completion
Principal Investigator
by Ali Mahtabifard, MD

Description

Summary

The aim of this study is to sample and analyze volatile organic compounds (VOCs) from lung cancer patients and individuals without lung cancer ("healthy" controls). The breath sample analysis will help investigators describe and identify profiles of VOCs found in the breath of patients with lung cancer when compared to normal breath profiles using infrared spectroscopy. This work will help validate early proof of concept results conducted with prototype technology and later stage NSCLC breath samples, and inform future breath testing analysis.

Official Title

Analysis of Volatile Chemicals in the Breath of Lung Cancer Patients Using Infrared Spectroscopy

Details

Globally, lung cancer accounts for the most cancer deaths in both sexes combined. It is believed to develop slowly through progressive accumulation of genetic mutations, hence the disease allows time for diagnosis and curative surgical treatment. Five year survival rates for non-small-cell lung carcinoma (NSCLC) can range from 57-61% when detected in the early stages of disease. This is compared with a survival rate of approximately 6% once distant metastases are present. However, disease diagnosis typically occurs when it has progressed to an advanced stage when patients present with signs and symptoms. Therefore, technologies capable of asymptomatic disease detection will significantly impact lung cancer specific mortality. Metabolomic profiling of cancer measures compounds produced as a result of cellular activity including volatile organic compounds (VOCs) in exhaled breath. Infrared spectroscopy is a proven technique for breath analysis that can measure chemical concentrations in the parts per trillion range for certain VOCs. When coupled with machine learning techniques, this has the potential to be a novel approach for disease detection using exhaled breath.

Keywords

Lung Cancer Non Small Cell Lung Cancer Volatile Organic Compounds Breath Analysis Infrared Spectroscopy Lung Neoplasms

Eligibility

You can join if…

Open to people ages 18 years and up

LC Group:

  • ≥ 18 years;
  • Able to give informed consent;
  • Eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery);
  • Clinical evidence of lung cancer (metastatic or primary), inclusive of those receiving non-curative treatment, has not yet been treated or is not currently on treatment;
  • No history of or any other active cancer;
  • Able to provide a breath sample;

Control Group:

  • ≥ 18 years;
  • Able to give informed consent;
  • Eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery);
  • No history of lung cancer or any other active cancer and is eligible for lung cancer screening;
  • Able to provide a breath sample;

You CAN'T join if...

  • Has received or is currently receiving curative treatment and may no longer have lung cancer;
  • Cannot give informed consent;

Location

  • University of California, Irvine Medical Center
    Orange California 92868 United States

Lead Scientist at UC Irvine

  • Ali Mahtabifard, MD
    Associate Clinical Professor, Surgery. Authored (or co-authored) 15 research publications.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Picomole Inc
Links
American Cancer Society. Cancer Facts & Figures 2019. American Cancer Society. Non-Small Cell Lung Cancer Survival Rates (2016)
ID
NCT04556435
Study Type
Observational
Last Updated